Table 3.
Roles and Mechanisms of lncRNAs in BC chemotherapy.
| Drug | LncRNA | Role | Mechanism |
|---|---|---|---|
| Paclitaxel | FTH1P3 (116) | Inducing | FTH1P3 acts as a sponge of miR-206 and increases expression of ABCB1 to trigger paclitaxel resistance |
| LINC00160 (117) | Inducing | LINC00160 up-regulates TFF3 by recruited C/EBPα to promote paclitaxel resistance of MCF-7 cells | |
| MAPT-AS1 (118) | Inducing | MAPT-AS1 upregulates MAPT and its protein TAU, which competes against paclitaxel at the microtubules | |
| EGOT (119) | Blocking | EGOT enhances autophagosome accumulation by increasing ITPR1 expression, thereby sensitizes BC cells to paclitaxel | |
| Docetaxel | EPB41L4A-AS2 (120) | Blocking | EPB41L4A-AS2 promotes docetaxel sensitivity by activating ABCB1 |
| H19 (121) | Inducing | H19 targets and sustains PARP-1 activity to mediate the resistance of BC cells and patients | |
| Doxorubicin | MALATI (79) | Inducing | MALAT1 targets miR-570-3P to decrease sensitivity of BC cells to doxorubicin |
| SAMMSON (122) | Inducing | SAMMSON increases glycolysis and decreases mitochondrial respiration, leading to doxorubicin resistance | |
| SNHG10 (123) | Blocking | SNHG10 up-regulates miR-302b via promoting methylation, and enhances doxorubicin sensitivity of TNBC cells | |
| Epirubicin | lnc005620 (124) | Inducing | lnc005620 upregulates ITGB1 and decreases the effects of epirubicin |
| NONHSAT101069 (125) | Inducing | NONHSAT101069 promotes epirubicin resistance via NONHSAT101069/miR-129-5p/Twist1 axis in BC cells | |
| Cisplatin | DANCR (126) | Inducing | DANCR upregulates KLF5 and induces the cisplatin resistance in TNBC patients by inhibiting p27 |
| HULC (127) | Inducing | HULC upregulates IGF1R and increases the expression of tumor stem cell markers to enhance cisplatin resistance | |
| 5-fluorouracil | CCAT2 (128) | Inducing | CCAT2 activates mTOR pathway to trigger 5-Fu resistance |
| SNORD3A (129) | Blocking | Sponges miR185-5p and upregulates UMPS to increase 5-FU sensitivity |